Rocket Pharmaceuticals’ (RCKT) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $11.00 target price on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald upped their price objective on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a research note on Friday, December 19th. Wall Street Zen downgraded shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. The Goldman Sachs Group increased their price target on shares of Rocket Pharmaceuticals to $3.00 and gave the company a “sell” rating in a research report on Monday, March 2nd. Finally, Lifesci Capital upgraded shares of Rocket Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.79.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock opened at $3.77 on Friday. The firm has a market cap of $411.38 million, a price-to-earnings ratio of -1.88 and a beta of 0.39. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $8.26. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $4.03 and its 200 day moving average is $3.64.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. During the same period in the previous year, the business posted ($0.62) EPS. On average, sell-side analysts anticipate that Rocket Pharmaceuticals will post -2.83 EPS for the current fiscal year.

Insider Buying and Selling

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 12,279 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the completion of the transaction, the chief executive officer owned 1,052,045 shares of the company’s stock, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel owned 683,376 shares of the company’s stock, valued at $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 29,415 shares of company stock valued at $97,398 over the last quarter. 24.76% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. acquired a new stake in Rocket Pharmaceuticals during the 2nd quarter worth about $25,000. CANADA LIFE ASSURANCE Co grew its stake in Rocket Pharmaceuticals by 94.4% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 5,926 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Rocket Pharmaceuticals in the fourth quarter valued at about $38,000. Virtu Financial LLC purchased a new position in shares of Rocket Pharmaceuticals in the third quarter worth about $40,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals in the fourth quarter worth about $42,000. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals News Roundup

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: FDA approval of KRESLADI for severe pediatric LAD‑I — regulatory green light expands Rocket’s commercial path for a first‑in‑class gene therapy for a fatal childhood disorder; approval is narrowly targeted to patients without an HLA‑matched sibling donor, and the decision creates revenue potential and clinical/regulatory validation that could benefit the company’s pipeline. Proactive: Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
• Positive Sentiment: Industry and media coverage emphasize milestone nature and platform validation — outlets note the approval could “clear the way” for future Rocket products, which supports longer‑term upside if the company executes commercially. BioSpace: Rocket’s Gene Therapy Wins FDA Greenlight
• Positive Sentiment: Analyst reaffirmation with a high price target — Chardan Capital reiterated a Buy and set an $11 target, signaling street conviction and implying substantial upside from current levels if commercialization prospects materialize. Benzinga: Chardan reaffirms Buy, $11 PT
• Neutral Sentiment: Unusually large options activity — a surge in call buying (noted the prior day) indicates speculative/short‑term trader interest around the approval news; this can amplify volatility but doesn’t directly change fundamentals. Seeking Alpha transcript and options note
• Negative Sentiment: Commercial and execution risks remain — small patient population for LAD‑I, reimbursement/pricing negotiations, manufacturing scale‑up, and post‑approval commitments (including potential confirmatory trials) could limit near‑term revenue and increase spending; these uncertainties explain why shares remain volatile and below some long‑term targets until commercial traction is shown. Reuters: Coverage of approval and market reaction

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.